<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-166743</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Perioperative management of vitamin K antagonists in patients with low thromboembolic risk undergoing elective surgery: A prospective experience</dc:title>
<dc:description xml:lang="en">Background and objectives: To quantify thromboembolic and bleeding events in patients with low thromboembolic risk, who were chronically receiving vitamin K antagonists and undergoing elective surgery. Material and methods: A descriptive, prospective, single-center study was conducted between December 2010 and July 2014. Patients aged over 18 years old, chronically anticoagulated with vitamin K antagonists and admitted for elective surgery were included in the study. We excluded patients with a creatinine clearance&lt;30ml/min, a body weight&gt;120kg, heparin-induced thrombocytopenia, pregnant women, carriers of an epidural catheter for analgesia, patients who underwent unscheduled surgery and high thromboembolic risk-patients. Vitamin K antagonists were discontinued 5 days prior to the procedure without administering anticoagulant enoxaparin. The NIR was measured 24h before the procedure. A single dose of 3mg of vitamin K was administered in cases of a NIR&gt;1.5. Vitamin K antagonists was resumed according to the surgical bleeding risk. Events were registered between 5 days prior to the procedure until 30 days after it. Results: A total of 75 procedures were included in the study. Fifty-six patients (74.7%) received vitamin K antagonists for atrial fibrillation, 15 suffered from venous thromboembolism (20%) and 4 had mechanical heart valves (5.3%). Twenty-six patients (34.5%) underwent high-bleeding risk surgeries and 49 (65.5%) underwent low risk procedures. No thromboembolic event was recorded. Four bleeding events (5.3%) were reported, 3 of which were considered major bleeding events (2 fatal). Conclusions: Suspending vitamin K antagonists with no bridging therapy performed in patients with a low thromboembolic risk does not expose such patients to a significant risk of embolic events (AU)</dc:description>
<dc:creator>Cornavaca, María Teresita</dc:creator>
<dc:creator>Albertini, Ricardo</dc:creator>
<dc:creator>Tabares, Aldo Hugo</dc:creator>
<dc:creator>Florencia Becerra, Ana</dc:creator>
<dc:creator>Revigliono, José Ignacio</dc:creator>
<dc:creator>Contreras, Alejandro</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento y objetivos: Se cuantificó la ocurrencia de episodios hemorrágicos y tromboembólicos en pacientes anticoagulados con antagonistas de vitamina K con bajo riesgo de tromboembolia, sometidos a un procedimiento invasivo electivo. Material y métodos: Se realizó un estudio descriptivo, prospectivo, unicéntrico entre diciembre de 2010 y julio de 2014. Se incluyeron pacientes mayores de 18 años, anticoagulados crónicamente con cumarínicos que ingresaron para realizar cirugía electiva. Se excluyeron los pacientes con aclaramiento de creatinina&lt;30ml/min, peso&gt;120kg, trombocitopenia inducida por heparina, embarazadas, catéter peridural para analgesia, cirugías no programadas y aquellos con alto riesgo tromboembólico. Se suspendió el antagonista de vitamina K 5 días antes del procedimiento sin administrar enoxaparina anticoagulante. Se midió RIN 24h antes del procedimiento y se administraron 3mg de vitamina K si este era mayor de 1,5. En el postoperatorio se reinició cumarínico según el riesgo de hemorragia asociado al procedimiento quirúrgico. Se evaluaron los episodios embólicos y hemorrágicos ocurridos desde el día 5 anterior al procedimiento hasta 30 días después de este. Resultados: Se registraron 75 procedimientos. En 56 casos (74,7%) los pacientes estaban anticoagulados por fibrilación auricular, 15 por tromboembolismo venoso (20%) y 4 por válvula cardíaca mecánica (5,3%). Veintiséis pacientes (34,5%) se sometieron a cirugías de alto riesgo de hemorragia y 49 (65,5%) de bajo riesgo. No se registró ningún episodio tromboembólico y acontecieron 4 (5,3%) episodios hemorrágicos; 3 (4%) correspondieron a hemorragias mayores (2, mortales). Conclusiones: Suspender la anticoagulación con cumarínicos sin tratamiento puente en pacientes de bajo riesgo de tromboembolia no expondría a estos a la ocurrencia de episodios embólicos (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);149(7): 281-286, oct. 2017. ilus, tab</dc:source>
<dc:identifier>ibc-166743</dc:identifier>
<dc:title xml:lang="es">Experiencia prospectiva en el uso perioperatorio de antagonistas de vitamina K en pacientes de bajo riesgo tromboembólico que reciben cirugía electiva</dc:title>
<dc:subject>^d1287^s22057</dc:subject>
<dc:subject>^d54247</dc:subject>
<dc:subject>^d14308^s22054</dc:subject>
<dc:subject>^d28612</dc:subject>
<dc:subject>^d15213^s22006</dc:subject>
<dc:subject>^d932^s28898</dc:subject>
<dc:subject>^d31021^s22045</dc:subject>
<dc:subject>^d28607</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28875^s22054</dc:subject>
<dc:subject>^d3389^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201710</dc:date>
</metadata>
</record>
</ibecs-document>
